Cocrystal Pharma, Inc. announced that the last subject has been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections. The randomized, double-blind, placebo-controlled trial was conducted at Emory University School of Medicine using healthy subjects infected with the norovirus GII.2 strain. Preliminary efficacy results are expected in late 2026 or early 2027. CDI-988 is an oral antiviral designed to inhibit viral replication and has previously demonstrated safety in Phase 1 trials. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics.
